- Home
- CMMB vs RDHL Comparison
CMMB vs RDHL Comparison
Compare CMMB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- RDHL
- Stock Information
- Founded
- CMMB 2004
- RDHL 2009
- Country
- CMMB Israel
- RDHL Israel
- Employees
- CMMB N/A
- RDHL N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- RDHL Health Care
- Exchange
- CMMB Nasdaq
- RDHL Nasdaq
- Market Cap
- CMMB 15.8M
- RDHL 13.1M
- IPO Year
- CMMB N/A
- RDHL N/A
- Fundamental
- Price
- CMMB $1.51
- RDHL $8.16
- Analyst Decision
- CMMB Strong Buy
- RDHL
- Analyst Count
- CMMB 3
- RDHL 0
- Target Price
- CMMB $5.67
- RDHL N/A
- AVG Volume (30 Days)
- CMMB 206.1K
- RDHL 37.3K
- Earning Date
- CMMB 11-07-2024
- RDHL 10-15-2024
- Dividend Yield
- CMMB N/A
- RDHL N/A
- EPS Growth
- CMMB N/A
- RDHL N/A
- EPS
- CMMB N/A
- RDHL N/A
- Revenue
- CMMB N/A
- RDHL $3,707,000.00
- Revenue This Year
- CMMB N/A
- RDHL $224.90
- Revenue Next Year
- CMMB N/A
- RDHL $82.69
- P/E Ratio
- CMMB N/A
- RDHL N/A
- Revenue Growth
- CMMB N/A
- RDHL N/A
- 52 Week Low
- CMMB $0.42
- RDHL $6.43
- 52 Week High
- CMMB $2.55
- RDHL $82.00
- Technical
- Relative Strength Index (RSI)
- CMMB 43.28
- RDHL 40.13
- Support Level
- CMMB $1.29
- RDHL $7.95
- Resistance Level
- CMMB $1.58
- RDHL $9.05
- Average True Range (ATR)
- CMMB 0.15
- RDHL 0.61
- MACD
- CMMB -0.04
- RDHL -0.20
- Stochastic Oscillator
- CMMB 39.29
- RDHL 6.73
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.